Last reviewed · How we verify

Protamin

University of Ioannina · FDA-approved active Small molecule Under review

Protamin is a Small molecule drug developed by University of Ioannina. It is currently FDA-approved for Heparin overdose. Also known as: viscoelastic testing (Clot-Pro), ACT.

Protamin is a heparin inhibitor, classified as an INHIBITOR drug. It is used to treat various conditions including Low Cardiac Output, Cardiac Surgery, CAD, Valve Heart Disease, and Coagulation Disorder.

At a glance

Generic nameProtamin
Also known asviscoelastic testing (Clot-Pro), ACT
SponsorUniversity of Ioannina
ModalitySmall molecule
Therapeutic areaOther
PhaseFDA-approved

Approved indications

Common side effects

Serious adverse events

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Protamin

What is Protamin?

Protamin is a Small molecule drug developed by University of Ioannina, indicated for Heparin overdose.

What is Protamin used for?

Protamin is indicated for Heparin overdose.

Who makes Protamin?

Protamin is developed and marketed by University of Ioannina (see full University of Ioannina pipeline at /company/university-of-ioannina).

Is Protamin also known as anything else?

Protamin is also known as viscoelastic testing (Clot-Pro), ACT.

What development phase is Protamin in?

Protamin is FDA-approved (marketed).

What are the side effects of Protamin?

Common side effects of Protamin include Hypoglycemia, Headache, Influenza-like symptoms, Upper respiratory tract infection, Dyspepsia, Headache. Serious adverse events: Severe Hypoglycemia, Severe Hypoglycemia, Anaphylaxis, Worsening of diabetic retinopathy.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing